On January 18, 2022, the Pan-Canadian Formulary Advisory Panel will be presenting an information session with their recommendations for the development of a framework for a potential pan-Canadian prescription drug list, or formulary.
The Advisory Panel was established by the Canadian Agency for Drugs and Technologies in Health (CADTH) at the request of Health Canada. The information session will focus on the principles for developing a pan-Canadian formulary framework, a sample list of prescribed drugs to include on the potential formulary as a test case, and criteria and processes for expanding the sample list. Registration is free.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Update on biosimilars in Canada – March 2023
In this article, we provide a further update on developments regarding biosimilars in Canada.Read More -
CADTH consultation on time-limited reimbursement initiative, and IMC report on what Canada can learn from Europe
The Canadian Agency for Drugs and Technologies in Health has released a consultation document for a Proposed Process for Time-limited Reimbursement Recommendations.Read More -
House of Commons Standing Committee on Health meets for study of the PMPRB
The Standing Committee on Health (HESA) of the House of Commons met on Thursday, April 27, 2023, to begin its study of the Patented Medicine Prices Review Board (PMPRB).Read More